Serving hundreds of leading biopharmaceutical companies globally:

Generated: October 17, 2018

DrugPatentWatch Database Preview

Janssen Prods Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PRODS, and what generic alternatives to JANSSEN PRODS drugs are available?

JANSSEN PRODS has seven approved drugs.

There are thirty-three US patents protecting JANSSEN PRODS drugs.

Summary for Janssen Prods

US Patents:	33
Tradenames:	6
Ingredients:	6
NDAs:	7

Drugs and US Patents for Janssen Prods

+ Get email alerts for changes to this table

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-002	Feb 25, 2008	AB	RX	Yes	No	7,470,506*PED	➤ Sign Up			Y	➤ Sign Up
Janssen Prods	SYMTUZA	cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210455-001	Jul 17, 2018		RX	Yes	Yes		➤ Sign Up				➤ Sign Up
Janssen Prods	OLYSIO	simeprevir sodium	CAPSULE;ORAL	205123-001	Nov 22, 2013		DISCN	Yes	No		➤ Sign Up				➤ Sign Up
Janssen Prods	OLYSIO	simeprevir sodium	CAPSULE;ORAL	205123-001	Nov 22, 2013		DISCN	Yes	No	8,754,106	➤ Sign Up		Y		➤ Sign Up
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-006	Nov 9, 2012		RX	Yes	Yes	9,889,115	➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Expired US Patents for Janssen Prods

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-001	Jun 23, 2006	6,037,157*PED	➤ Sign Up
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-002	Feb 25, 2008	5,843,946*PED	➤ Sign Up
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-003	Oct 21, 2008	RE43802*PED	➤ Sign Up
Janssen Prods	PREZISTA	darunavir ethanolate	TABLET;ORAL	021976-006	Nov 9, 2012	6,335,460*PED	➤ Sign Up
Janssen Prods	PREZISTA	darunavir ethanolate	SUSPENSION;ORAL	202895-001	Dec 16, 2011	6,703,403*PED	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	800 mg	➤ Subscribe	2013-05-14

International Patents for Janssen Prods Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Country	Document Number	Estimated Expiration
Ukraine	92469	➤ Sign Up
Peru	09252006	➤ Sign Up
Denmark	0984013	➤ Sign Up
Austria	508748	➤ Sign Up
Finland	20060622	➤ Sign Up
Country	Document Number	Estimated Expiration

Supplementary Protection Certificates for Janssen Prods Drugs

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2015000088	Germany	➤ Sign Up	PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
0150039 00166	Estonia	➤ Sign Up	PRODUCT NAME: RILPIVIRIINI (VESINIKKLORIIDSOOLANA) JA EMTRITSITABIINI;REG NO/DATE: EU/1/11/737/001-002 28.11.2011
2016045	Lithuania	➤ Sign Up	PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621
2012008,C1419152	Lithuania	➤ Sign Up	PRODUCT NAME: RILPIVIRINUM; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
16/061	Ireland	➤ Sign Up	PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REGISTRATION NO/DATE: EU/1/15/1061 20151119
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson

Fuji

Queensland Health

Citi

Medtronic

Cerilliant

Merck

Covington

Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.